RBC Capital analyst Conor McNamara maintained a Buy rating on Maravai Lifesciences Holdings (MRVI – Research Report) on February 4 and set a ...

In a report released today, Matt Hewitt from Craig-Hallum maintained a Buy rating on Maravai Lifesciences Holdings (MRVI – Research Report).

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI – Get Free Report) was the recipient of unusually large options trading activity on Wednesday. Stock traders acquired 1,002 put options on the company.

In this article, we are going to take a look at where Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) stands against other stocks under $5 with biggest upside potential. On January 20 ...

KURT ORESHACK, the General Counsel of $MRVI, sold 25,000 shares of the company on 01-31-2025 for an estimated $125,750. We received data on the trade from a recent ...

Maravai LifeSciences stock opened at $4.77 on Wednesday. Maravai LifeSciences has a 52-week low of $4.28 and a 52-week high of $11.56. The company has a quick ratio of 9.94, a current ratio of 10. ...

SAN DIEGO--(BUSINESS WIRE)--Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and ...

View Maravai LifeSciences Holdings, Inc. (MRVI) current and estimated P/E ratio data provided by Seeking Alpha.

Announces Earnings Release DateSAN DIEGO, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to ...

In this article, we are going to take a look at where Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) stands against other stocks under $5 with biggest upside potential. On January 20 ...